6.1 Chronic Kidney Disease: KDIGO Guidelines & SGLT2i/nsMRA Care

Chronic Kidney Disease: KDIGO Guidelines & SGLT2i/nsMRA Care

Executive Summary: Chronic Kidney Disease (CKD) affects over 10% of the global adult population and represents a major multiplier of cardiovascular morbidity, all-cause mortality, and progression to end-stage kidney disease (ESKD). For the Board Certified Ambulatory Care Pharmacist (BCACP), mastering the Kidney Disease: Improving Global Outcomes (KDIGO) guidelines requires deep command of 2-dimensional CGA staging, intensive blood pressure control (<120 mmHg standardized SBP), foundational renin-angiotensin-aldosterone system (RAAS) blockade, the paradigm-shifting application of sodium-glucose cotransporter 2 (SGLT2) inhibitors and non-steroidal mineralocorticoid receptor antagonists (nsMRAs), and the precise correction of downstream mineral, electrolyte, and hematologic complications.

---

1. KDIGO Definition, Diagnostic Criteria & 2-Dimensional CGA Staging Heatmap

Under KDIGO guidelines, Chronic Kidney Disease (CKD) is defined as abnormalities of kidney structure or function persisting for greater than 3 months with implications for health. A diagnosis requires either:

1. Decreased Glomerular Filtration Rate (GFR): eGFR < 60 mL/min/1.73m² for > 3 months.
2. Markers of Kidney Damage (one or more):
   • Albuminuria (Urinary Albumin-to-Creatinine Ratio [UACR] ≥ 30 mg/g or ≥ 3 mg/mmol).
   • Urine sediment abnormalities (e.g., dysmorphic RBCs, RBC casts, WBC casts, tubular epithelial casts).
   • Electrolyte and other abnormalities due to tubular disorders (e.g., renal tubular acidosis, nephrogenic diabetes insipidus).
   • Histological abnormalities detected on renal biopsy.
   • Structural abnormalities detected by imaging (e.g., polycystic kidneys, renal artery stenosis, hydronephrosis, solitary kidney).
   • History of kidney transplantation.

The CGA Staging Framework

KDIGO classifies CKD based on CGA: Cause (etiology such as diabetic nephropathy, hypertensive glomerulosclerosis, glomerulonephritis, polycystic kidney disease), GFR category (G1 to G5), and Albuminuria category (A1 to A3).

The KDIGO Prognostic Heatmap & Monitoring Frequency

The intersection of GFR and Albuminuria categories dictates composite clinical risk (progression to kidney failure, acute kidney injury [AKI], cardiovascular hospitalization, and all-cause mortality):

• Low Risk (Green / Stage G1-G2 with A1): Screen/monitor annually.
• Moderate Risk (Yellow / Stage G3a-A1 or G1-G2 with A2): Reassess eGFR and UACR at least once yearly.
• High Risk (Orange / Stage G3b-A1, G3a-A2, or G1-G2 with A3): Monitor eGFR and UACR 2 times per year.
• Very High Risk (Red / Stage G4-G5 or G3b-A2, G3a-A3, G3b-A3): Monitor eGFR, UACR, and electrolytes 3 to 4+ times per year; refer promptly to nephrology.

2. Blood Pressure Targets & Renin-Angiotensin-Aldosterone System (RAAS) Inhibition

Standardized Blood Pressure Targets in Non-Dialysis CKD

Blood pressure control slows renal function loss and mitigates excessive cardiovascular risk. The KDIGO Clinical Practice Guideline for Blood Pressure in CKD recommends:

Target Standardized SBP: < 120 mmHg

• Standardized Measurement Requirement: This intensive target is derived from the SPRINT trial (CKD Subgroup) and applies only when blood pressure is measured using standardized, automated office blood pressure (AOBP) techniques in seated patients after 5 minutes of quiet rest. Casual or non-standardized auscultatory readings should not be titrated to < 120 mmHg due to risks of orthostatic syncope, fall-related injuries, and acute hypoperfusion.
• Clinical Caveats: A less intensive target (< 130/80 mmHg) is appropriate in very elderly or frail patients, those with advanced Stage 4–5 CKD, symptomatic orthostatic hypotension, or severe baseline autonomic dysfunction.

First-Line RAAS Blockade: ACE Inhibitors & ARBs

Angiotensin-converting enzyme inhibitors (ACEis) and Angiotensin II Receptor Blockers (ARBs) reduce intraglomerular hydrostatic capillary pressure by preferentially dilating the efferent arteriole, thereby decreasing glomerular hyperfiltration, wall tension, and proteinuria.

+---------------------------------------------------------------------------------------+
|                   INDICATIONS FOR FIRST-LINE ACE INHIBITOR OR ARB THERAPY             |
+------------------------------------+--------------------------------------------------+
| Clinical Patient Phenotype         | Guideline Recommendation Level                   |
+------------------------------------+--------------------------------------------------+
| CKD with Albuminuria A3            | Strong Recommendation (Grade 1B)                 |
| (UACR >300 mg/g) without Diabetes  | (Titrate to highest approved/tolerated dose)     |
+------------------------------------+--------------------------------------------------+
| CKD with Albuminuria A2            | Strong Recommendation (Grade 1B)                 |
| (UACR 30-300 mg/g) WITH Diabetes   | (Titrate to highest approved/tolerated dose)     |
+------------------------------------+--------------------------------------------------+
| CKD with Albuminuria A2            | Conditional Recommendation (Grade 2C)            |
| (UACR 30-300 mg/g) without Diabetes| (May consider ACEi/ARB to reduce progression)    |
+------------------------------------+--------------------------------------------------+

The "Permissible Dip" Rule in Serum Creatinine

Following initiation or upward titration of an ACEi or ARB, the clinician must obtain repeat serum creatinine (SCr), eGFR, and serum potassium in 2 to 4 weeks:

• Acceptable Hemodynamic Effect: A rise in serum creatinine of up to 30% from baseline (or a corresponding decline in eGFR up to 30%) is an expected, reversible consequence of reduced intraglomerular pressure and correlates with long-term preservation of renal parenchyma. Do NOT reduce the dose or discontinue therapy.
• Unacceptable Elevation (>30% rise): If SCr increases by > 30%, evaluate for volume depletion, excessive diuresis, concomitant NSAID therapy, severe renal artery stenosis (bilateral or solitary kidney), or acute obstructive uropathy. Temporarily reduce or withhold the RAAS inhibitor while correcting underlying precipitants.

Absolute Practice Warning — Dual RAAS Blockade: Combining an ACE inhibitor with an ARB or a direct renin inhibitor (aliskiren) is strictly contraindicated. Landmark randomized trials (ONTARGET, ALTITUDE, VA NEPHRON-D) demonstrated that dual RAAS blockade produces no additional renal or cardiovascular benefit while significantly increasing rates of hyperkalemia, acute kidney injury, and symptomatic hypotension.

3. SGLT2 Inhibitors: The Transformative Pillar of CKD Care

Sodium-Glucose Cotransporter 2 (SGLT2) inhibitors have revolutionized nephrology, transitioning from antidiabetic agents to universal disease-modifying therapies for chronic kidney disease, regardless of diabetes status.

Pharmacodynamic Mechanism in the Nephron

1. Restoration of Tubuloglomerular Feedback: In diabetic and non-diabetic CKD, hyperfiltration is driven by proximal tubular sodium and glucose hyper-reabsorption. SGLT2 inhibitors block sodium-glucose cotransport in the S1 segment of the proximal convoluted tubule, delivering increased sodium chloride to the macula densa.
2. Afferent Arteriolar Vasoconstriction: The macula densa releases adenosine, which constricts the dilated afferent arteriole, reducing intraglomerular hypertension and attenuating structural barotrauma.
3. Metabolic & Anti-inflammatory Effects: Reduces renal cortical hypoxia, decreases glucotoxicity, downregulates pro-fibrotic cytokines (TGF-beta, TNF-alpha), and promotes systemic ketogenesis providing efficient cardiac/renal substrate.

Landmark Trial Evidence Summary

KDIGO Clinical Implementation Rules for SGLT2 Inhibitors

1. Initiation Threshold: Initiate an SGLT2 inhibitor (Dapagliflozin 10 mg daily, Empagliflozin 10 mg daily, or Canagliflozin 100 mg daily) in all adults with:
   • Type 2 Diabetes and CKD with eGFR ≥ 20 mL/min/1.73m².
   • Non-diabetic CKD with eGFR ≥ 20 mL/min/1.73m² and UACR ≥ 200 mg/g (or comorbid Heart Failure with reduced/preserved ejection fraction).
2. The Continuation Rule (Never Stop for Low eGFR): While glycemic lowering wanes when eGFR drops < 45 mL/min/1.73m², renal and cardiovascular benefits persist down to dialysis. Once an SGLT2 inhibitor is initiated at eGFR ≥ 20, continue therapy even if eGFR falls below 20 mL/min/1.73m², until kidney replacement therapy (dialysis or transplantation) is initiated or the drug is not tolerated.
3. Initial Hemodynamic eGFR "Dip": A predictable, acute decline in eGFR of 3 to 5 mL/min/1.73m² occurs within the first 2 to 4 weeks due to afferent arteriolar constriction. This is a functional marker of therapeutic hemodynamic unloading, not structural tubular damage. Long-term eGFR decline slows dramatically compared to placebo.
4. Safety & Adverse Event Mitigation:
   • Euglycemic Diabetic Ketoacidosis (euDKA): Instruct patients on sick-day rules; temporarily withhold SGLT2i at least 3 days before major elective surgery, during prolonged fasting, severe acute illness, or excessive alcohol intake.
   • Mycotic Genital Infections: Counsel on daily perineal hygiene and hydration; treat candida infections with topical or short-course oral antifungals without necessarily discontinuing the SGLT2i.
   • Volume Depletion / Hypotension: If baseline BP is low or patient is on high-dose loop diuretics, consider a modest reduction in diuretic dose prior to SGLT2i initiation.

4. Non-Steroidal Mineralocorticoid Receptor Antagonists: Finerenone

In diabetic kidney disease, persistent overactivation of the mineralocorticoid receptor (MR) drives chronic inflammation, endothelial dysfunction, and interstitial fibrosis in renal tubules and myocardium. Traditional steroidal MRAs (spironolactone, eplerenone) are limited in CKD by severe hyperkalemia and endocrine adverse effects (gynecomastia, breast pain with spironolactone).

Pharmacodynamic Profile of Finerenone

• Selective Non-Steroidal Architecture: Bulky, non-steroidal structure binds the MR with high affinity and selectivity, acting as an antagonist that prevents MR cofactor recruitment without activating androgen or progesterone receptors.
• Balanced Tissue Distribution: Distributes equally between renal and cardiac tissues (spironolactone has 6-fold higher renal accumulation), translating to potent anti-inflammatory and antifibrotic activity with a lower incidence of severe hyperkalemia.
• Clinical Evidence: FIDELIO-DKD demonstrated an 18% RRR in composite renal outcomes (ESKD, sustained ≥ 40% eGFR decline, renal death) in T2D with CKD on maximal ACEi/ARB. FIGARO-DKD demonstrated a 13% RRR in composite cardiovascular outcomes (CV death, non-fatal MI, non-fatal stroke, HF hospitalization). The pooled FIDELITY analysis confirmed robust cardiorenal protection across early-to-late CKD stages.

Finerenone Dosing, Potassium Thresholds & Titration Algorithm

+---------------------------------------------------------------------------------------+
|                       FINERENONE CLINICAL INITIATION & TITRATION PROTOCOL              |
+------------------------------------+--------------------------------------------------+
| Clinical Parameter                 | Mandatory Clinical Rule                          |
+------------------------------------+--------------------------------------------------+
| Baseline Patient Eligibility       | T2D + CKD (eGFR >= 25 mL/min/1.73m², UACR >= 30  |
|                                    | mg/g) on maximum tolerated dose of ACEi or ARB   |
+------------------------------------+--------------------------------------------------+
| Mandatory Potassium Threshold      | Serum Potassium MUST be <= 4.8 mEq/L to initiate |
|                                    | (If K+ > 4.8 to 5.0, optimize diet; if > 5.0, hold|
+------------------------------------+--------------------------------------------------+
| Starting Dose (eGFR >= 60)         | 20 mg orally once daily                          |
+------------------------------------+--------------------------------------------------+
| Starting Dose (eGFR 25 to <60)     | 10 mg orally once daily                          |
+------------------------------------+--------------------------------------------------+
| Severe CKD (eGFR < 25)             | Initiation NOT recommended                       |
+------------------------------------+--------------------------------------------------+
| Mandatory 4-Week Monitoring        | Check Serum Potassium & SCr at 4 weeks           |
+------------------------------------+--------------------------------------------------+
| Titration Rule (from 10 mg daily)  | If K+ <= 4.8 mEq/L and eGFR stable: Increase to  |
|                                    | 20 mg once daily                                 |
|                                    | If K+ 4.9 to 5.5 mEq/L: Maintain 10 mg daily     |
|                                    | If K+ > 5.5 mEq/L: WITHHOLD finerenone; restart  |
|                                    | at 10 mg daily when K+ <= 5.0 mEq/L              |
+------------------------------------+--------------------------------------------------+

5. Ambulatory Hyperkalemia Management & Novel Potassium Binders

Hyperkalemia (K+ > 5.0 mEq/L, severe if > 6.0 mEq/L) is a frequent complication in CKD exacerbated by impaired distal tubular potassium excretion, metabolic acidosis, and the use of guideline-directed medical therapy (ACEi, ARB, nsMRAs, beta-blockers). Historical practice of abruptly discontinuing life-prolonging RAAS inhibitors is associated with increased cardiovascular and renal mortality. Modern ambulatory practice pairs dietary education with non-absorbed gastrointestinal potassium binders to maintain patients on optimal RAASi/nsMRA regimens.

Historical vs. Modern Potassium Binders

• Sodium Polystyrene Sulfonate (SPS / Kayexalate): Cation-exchange resin in exchange for sodium. Inefficient, unpredictable onset (hours to days), poor tolerability, high sodium burden, and carries an FDA warning for intestinal necrosis, bowel perforation, and ischemic colitis, particularly when administered with sorbitol. Not recommended for chronic ambulatory management.

Novel Cation Exchangers in Ambulatory Care

6. Renal Function Assessment & Drug Dosing Mathematics

Precise calculation of kidney function is critical for outpatient medication safety and dose optimization. Ambulatory care pharmacists must navigate the clinical dichotomy between historical FDA-approved package inserts and contemporary nephrology guidelines.

Cockcroft-Gault Creatinine Clearance (C-G CrCl)

The Cockcroft-Gault formula (1976) estimates creatinine clearance in mL/min (unadjusted for body surface area) and remains the mandated metric in the majority of FDA-approved package inserts (e.g., direct oral anticoagulants [DOACs], antimicrobials, SGLT2i historical labels):

$\text{CrCl (mL/min)} = \frac{(140 - \text{Age}) \times \text{Weight (kg)}}{72 \times \text{Serum Creatinine (mg/dL)}} \times (0.85 \text{ if Female})$

Weight Selection Protocol in Cockcroft-Gault Calculations

1. Underweight (Actual Weight [TBW] < Ideal Body Weight [IBW]): Use Actual Body Weight (TBW) to avoid overestimating clearance. $\text{IBW (Male)} = 50\text{ kg} + 2.3\text{ kg} \times (\text{Height in inches} - 60)$ $\text{IBW (Female)} = 45.5\text{ kg} + 2.3\text{ kg} \times (\text{Height in inches} - 60)$
2. Normal Weight (TBW is 100% to 120% of IBW): Use IBW (or TBW per institutional protocol; IBW is standard on BCACP examination items).
3. Overweight / Obese (TBW > 120% of IBW or BMI ≥ 30 kg/m²): Use Adjusted Body Weight (AdjBW) with an adiposity correction factor of 0.4: $\text{AdjBW} = \text{IBW} + 0.4 \times (\text{TBW} - \text{IBW})$

CKD-EPI (2021 Race-Free) eGFR Equation

• Expressed in mL/min/1.73m² (normalized to standard body surface area).
• Recommended by KDIGO, NKF, and ASN for CKD staging, epidemiological risk estimation, and clinical trial stratification.
• BSA De-Indexing for Drug Dosing: In patients with extreme body surface area (e.g., severe obesity or severe muscle wasting) receiving narrow therapeutic index drugs, de-index eGFR to mL/min before dosing: $\text{eGFR (mL/min)} = \text{eGFR (mL/min}/1.73\text{m}^2) \times \frac{\text{Patient BSA (m}^2)}{1.73}$

Board Exam Decision Rule: For medications with strict FDA boxed warnings and renal dosing cutoffs based on Cockcroft-Gault (such as apixaban, rivaroxaban, edoxaban, and dabigatran), calculate and utilize Cockcroft-Gault CrCl with appropriate weight selection.

7. Complications of CKD: Anemia & Mineral-Bone Disorder (CKD-MBD)

Anemia of Chronic Kidney Disease

Anemia of CKD is predominantly normocytic, normochromic and develops primarily from deficient erythropoietin (EPO) production by peritubular fibroblasts in the renal cortex, compounded by functional iron deficiency mediated by elevated hepcidin (which internalizes and degrades ferroportin, trapping iron in enterocytes and macrophages).

Diagnostic Workup & Iron Repletion Targets

Before initiating an Erythropoiesis-Stimulating Agent (ESA), non-renal causes of anemia (B12, folate deficiency, GI hemorrhage, hemolysis) must be ruled out and iron stores fully repleted.

• Transferrin Saturation (TSAT): Target ≥ 20% (optimal 20–50%).
• Serum Ferritin: Target ≥ 100 ng/mL for non-dialysis CKD; ≥ 200 ng/mL for hemodialysis-dependent CKD.
• Route of Administration: Oral iron (e.g., ferrous sulfate 325 mg [65 mg elemental iron] daily to TID on empty stomach, ferric maltol) is reasonable in non-dialysis CKD. However, if TSAT remains < 20% or oral iron causes intolerable GI adverse effects, Intravenous (IV) Iron (iron sucrose, ferric gluconate, ferric carboxymaltose, ferumoxytol) is superior and mandatory in hemodialysis.

Erythropoiesis-Stimulating Agents (ESAs) & Safety Thresholds

• Agents: Epoetin alfa (Epogen, Procrit: short-acting, 1–3x weekly), Darbepoetin alfa (Aranesp: hyperglycosylated, long-acting, once every 1–4 weeks), Methoxy polyethylene glycol-epoetin beta (Mircera: continuous receptor activator, q2–4 weeks).
• Initiation Rule: In non-dialysis CKD, consider ESA initiation ONLY when Hemoglobin drops < 10.0 g/dL, individualizing therapy to reduce the rate of red blood cell transfusions.
• Target Hemoglobin Ceiling: Maintain hemoglobin between 10.0 and 11.0 g/dL. DO NOT target hemoglobin > 11.5 g/dL (and never > 13.0 g/dL). Dose should be reduced by 25% or temporarily held if Hgb increases by > 1.0 g/dL over any 2-week period.

FDA Boxed Warning (TREAT, CHOIR, CREATE Trials): Targeting normal hemoglobin levels (> 13.0 g/dL) with ESAs in CKD causes a statistically significant increase in stroke, major adverse cardiovascular events (MI, heart failure hospitalization), venous thromboembolism, vascular access thrombosis, and all-cause mortality.

---

Chronic Kidney Disease-Mineral and Bone Disorder (CKD-MBD)

CKD-MBD is a systemic disorder characterized by biochemical abnormalities (calcium, phosphorus, PTH, FGF-23, vitamin D), bone histology defects (renal osteodystrophy), and vascular/valvular soft tissue calcification.

                               CKD-MBD PATHOPHYSIOLOGIC CASCADE
                               
    Loss of Functional Nephrons (Stage 3-5 CKD)
                 │
                 ├──> 1. Decreased Phosphate Excretion ──> HYPERPHOSPHATEMIA
                 │                                               │
                 ├──> 2. Loss of 1α-Hydroxylase (CYP27B1)        ├──> Binds Free Calcium
                 │         │                                     │         │
                 │         ▼                                     │         ▼
                 │    Decreased 1,25-(OH)2-D (Calcitriol)        │    HYPOCALCEMIA
                 │         │                                     │         │
                 │         ▼                                     │         │
                 │    Decreased Intestinal Ca2+ Absorption ──────┤         │
                 │                                                         ▼
                 └──> 3. Osteocytes Secrete FGF-23 ──────────> SECONDARY HYPERPARATHYROIDISM
                                                                           │
                                                                           ▼
                                                             Renal Osteodystrophy & Vascular Calcification

1. Dietary Phosphorus Restriction

Initial management in Stage 3–5 CKD involves restricting dietary phosphate to 800 to 1,000 mg/day by limiting processed foods, sodas, dairy, and inorganic phosphate preservatives.

2. Phosphate Binders (MUST Be Taken WITH MEALS)

Phosphate binders bind dietary phosphorus in the intestinal lumen, forming insoluble complexes excreted in feces. They are ineffective if taken between meals.

3. Vitamin D & Vitamin D Receptor Activators (VDRAs)

• Nutritional Vitamin D (Ergocalciferol D2, Cholecalciferol D3): Used in Stage 3–4 CKD if 25-hydroxyvitamin D is deficient (< 30 ng/mL). Ineffective at suppressing PTH in Stage 5 CKD due to lack of functional 1α-hydroxylase.
• Active Vitamin D (Calcitriol [1,25-(OH)2D3], Rocaltrol) & Selective VDRAs (Paricalcitol [Zemplar], Doxercalciferol [Hectorol]): Directly bind the parathyroid VDR to suppress PTH gene transcription. Paricalcitol has lower calcemic and phosphatemic activity than calcitriol, reducing hypercalcemia risk.

4. Calcimimetics

• Cinacalcet (Sensipar: 30 to 180 mg once daily with food): Allosteric activator of the Calcium-Sensing Receptor (CaSR) on the parathyroid gland. Increases the CaSR sensitivity to extracellular calcium, thereby suppressing PTH without increasing serum calcium or phosphorus (in fact, it lowers Ca and P).
• Mandatory Monitoring: Hypocalcemia risk. Do NOT initiate cinacalcet if baseline serum calcium (corrected for albumin) is < 8.4 mg/dL. Check calcium within 1 week of initiation or dose titration; frequent nausea/vomiting.
• Etelcalcetide (Parsabiv): Intravenous calcimimetic administered 3 times weekly at the end of hemodialysis sessions.